PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation by van Vuurden, Dannis G. et al.
www.impactjournals.com/oncotarget/  Oncotarget, December, Vol.2, No 12
Oncotarget 2011; 2:  984 - 996 984 www.impactjournals.com/oncotarget
PARP inhibition sensitizes childhood high grade glioma, 
medulloblastoma and ependymoma to radiation
Dannis G. van Vuurden1, Esther Hulleman1, Olga L.M. Meijer1, Laurine E. Wedekind1, 
Marcel Kool2, Hendrik Witt2,3, Peter W. Peter Vandertop4, Thomas Würdinger4,5, 
David P. Noske4, Gertjan J.L. Kaspers6 and Jacqueline Cloos6,7
1 Department of Pediatric Oncology / Hematology, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University 
Medical Center, Amsterdam, the Netherlands 
2 Department of Molecular Genetics of Childhood Brain Tumors, German Cancer Research Center (DKFZ), Heidelberg, 
Germany
3 Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
4 Departments of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, VU University Medical Center, 
Amsterdam, the Netherlands 
5 Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, 
Boston, MA, USA
6 Department of Pediatric Oncology / Hematology, VU University Medical Center, Amsterdam, the Netherlands
7 Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands 
Correspondence to: Dannis van Vuurden, email:dg.vanvuurden@vumc.nl
Keywords: PARP, radiation, medulloblastoma, ependymoma, glioma, pediatric
Received:  November 24, 2011, Accepted: December 9, 2011, Published: December 15, 2011
Copyright: © Van Vuurden et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT:
Poly ADP-ribose polymerase (PARP) is a protein involved in single strand break 
repair.  Recently, PARP inhibitors have shown considerable promise in the treatment 
of several cancers, both in monotherapy and in combination with cytotoxic agents. 
Synthetic lethal action of PARP inhibitors has been observed in tumors with 
mutations in double strand break repair pathways. In addition, PARP inhibition 
potentially enhances sensitivity of tumor cells to DNA damaging agents, including 
radiotherapy.  Aim of this study is to determine the radiosensitizing properties of 
the PARP inhibitor Olaparib in childhood medulloblastoma, ependymoma and high 
grade glioma (HGG). Increased PARP1 expression was observed in medulloblastoma, 
ependymoma and HGG, as compared to non-neoplastic brain tissue. Pediatric high 
grade glioma, medulloblastoma and ependymoma gene expression profiling revealed 
that high PARP1 expression is associated with poor prognosis. Cell growth inhibition 
assays with Olaparib resulted in differential sensitivity, with IC50 values ranging from 
1.4 to 8.4 µM, irrespective of tumor type and PARP1 protein expression. Sensitization 
to radiation was observed in medulloblastoma, ependymoma and HGG cell lines 
with subcytotoxic concentrations of Olaparib, which coincided with persistence of 
double strand breaks. Combining PARP inhibitors with radiotherapy in clinical 
studies in childhood high grade brain tumors may improve therapeutic outcome.
INTRODUCTION
Tumors of the central nervous system (CNS) are 
the second most common type of pediatric cancer after 
hematologic malignancies. Malignant childhood brain 
tumors have an incidence of 3.2 per 100,000 persons, 
with a large heterogeneity of classifying diagnoses. Most 
commonly observed high grade childhood brain tumors 
are embryonal tumors (WHO grade IV medulloblastoma 
and supratentorial PNET), high grade astrocytic tumors 
(WHO grade III anaplastic astrocytoma and WHO 
grade IV glioblastoma multiforme (GBM)) and high 
grade ependymal tumors (WHO grade III anaplastic 
ependymoma) [1]. Treatment of children diagnosed Oncotarget 2011; 2:  984 - 996 985 www.impactjournals.com/oncotarget
with a high grade malignant CNS tumor consists of a 
multimodal approach based on surgery, radiotherapy and 
chemotherapy. Despite improved treatment strategies and 
a higher chance of survival, especially in standard risk 
medulloblastoma, mortality is still considerably high in 
high risk medulloblastoma, ependymoma and HGG [2-7].
Radiotherapy is an essential part of the treatment 
although notorious for induction of late effects, not 
only to the developing cortex and deep brain structures, 
but also to the posterior fossa, with higher risk when 
applied at younger age [8-13]. Radiosensitizers may offer 
the opportunity to ameliorate the therapeutic index by 
increasing  the  efficacy  of  radiotherapy,  while  reducing 
the toxicity and damage to the developing brain. The 
therapeutic index can for instance be improved by 
targeting specific characteristics of the tumors cells such 
as their replication dependency and DNA repair defects. In 
particular, inhibitors of DNA repair are potential treatment 
options in highly proliferative high grade childhood brain 
tumors, arising in largely non-replicative normal tissues 
with proficient DNA repair.
Poly ADP-ribose polymerase (PARP) enzymes 
have an essential role in single strand break (SSB) DNA 
repair and currently there are several clinically relevant 
PARP inhibitors available. Upon DNA damage, PARP1 
is recruited to SSBs and the thereby induced PAR-chains, 
allow base-excision repair [14]. Moreover, PARP1 is 
involved in delaying the replication fork in homologous 
recombination (HR) proficient DNA damaged cells and 
in alternative pathways of non-homologous end joining 
(NHEJ) [15-17]. PARP inhibitors are in particular 
synthetically lethal in tumors with clear DNA repair 
deficiencies such  as  BRCA-  tumors.  However,  both in 
vitro and mice studies indicate the rationale to combine 
PARP inhibitors with DNA damaging agents in many 
different tumor types. Recently, PARP inhibitor Olaparib 
was shown to increase radiosensitivity of non-small cell 
lung cancer in vitro and in vivo, by inhibition of DNA 
repair and reduction of hypoxia by increased tumor 
perfusion [18]. Moreover, PARP inhibitors are being 
investigated in phase I and II clinical trials for multiple 
cancers, as chemo- and radiosensitizers [19, 20]
A recent study indicated the high expression of 
PARP1 in pediatric brain tumors, showing a significantly 
higher  PARP1 mRNA and protein expression in high-
grade pediatric brain tumors, compared to their low-grade 
counterparts [21]. In addition, PARP1 protein expression 
was found in medulloblastoma patients including cell 
lines [22, 23]. These studies indicate that PARP1 may 
be a potential treatment target in these tumors. Therefore 
we investigated whether high PARP1 expression is 
a biomarker of unfavorable prognosis in high grade 
pediatric CNS tumors. Moreover, we studied the rationale 
for combining PARP inhibitors with radiotherapy in 
patients with high PARP1 expression by determining the 
radiosensitizing properties of PARP1 inhibitors in these 
tumors using in vitro model systems.
MATERIAL AND METHODS
In silico analysis
R2, a microarray analysis and visualization platform, 
provided by the Department of Human Genetics of the 
Academic Medical Centre, Amsterdam, The Netherlands 
(http://r2.amc.nl), was used to obtain an overview of 
PARP1 mRNA expression in high grade pediatric brain 
tumors. MAS5.0 normalized datasets of childhood 
HGG (n=53; GSE19578) [24], medulloblastoma (n=62; 
GSE10327) [25] and ependymoma (n=19; GSE13267) 
were compared to normal prefrontal cortex (n=44; 
GSE13564) [26] and normal cerebellum (n=9; GSE3526) 
[27]. Clinical relevance of PARP expression was evaluated 
in an independent ependymoma cohort (GSE27287)[28].
Cell lines and cell culture
We used the pediatric brain tumor cell lines Res196 
(fossa posterior ependymoma; Dr. Michael S. Bobola, 
Seattle Children’s Hospital Research Institute)[29], 
SF188 and KNS42 (glioblastoma), UW479 (anaplastic 
astrocytoma), D283-med, D556-med (Dr. Darrell Bigner, 
Duke University) and UW228-2 (medulloblastoma). Cell 
lines  were  maintained  in  Dulbecco’s  Modified  Eagle 
Medium (DMEM; PAA Laboratories GmbH, Pasching, 
Austria) containing stable glutamine and sodium 
pyruvate, supplemented with 1% penicillin/streptomycin 
(PAA Laboratories GmbH, Pasching, Austria) and 10% 
fetal bovine serum (FBS; PerBio Science Nederland B.V., 
Etten-Leur, The Netherlands). D283-med and D556-med 
cells were cultured in medium as above, without sodium 
pyruvate. 
Immunohistochemistry
Paraffin  embedded  4  μm  histological  sections 
of 20 pediatric ependymomas (WHO grade II/III), 13 
HGG (WHO grade III/IV) and a tissue microarray of 92 
medulloblastomas were deparaffinized and rehydrated by 
washing the slides in a xylene and ethanol series. Sections 
were washed in water, endogenous peroxidase activity 
was quenched by a 30-minute incubation in 0.3% H2O2 in 
methanol, followed by washing in water. Antigen retrieval 
was performed with the sections in a 10 mM citrate buffer 
(pH 6.0) using a microwave oven. After washing in 
water and PBS, sections were incubated overnight at 4°C 
with previously validated mouse anti-PARP1 antibody 
(#556362; BD Pharmingen, San Diego, CA, USA), 
diluted 1:500 in normal antibody diluent (Immunologic, Oncotarget 2011; 2:  984 - 996 986 www.impactjournals.com/oncotarget
Duiven, The Netherlands). After thorough washing in 
PBS, sections were incubated for 15 minutes with post 
antibody blocking for PowerVision plus (Immunologic). 
Sections were subsequently rinsed in PBS and incubated 
with undiluted PowerVision plus Poly-HRP-anti Ms/Rb/
Rt IgG (Immunologic) for 30 minutes and washed again 
in PBS. The antibody-peroxidase complex was detected 
by incubating the sections with 3,3’-diaminobenzidine 
solution (Envision-DAB, 1:50, DAKO, Glostrup, 
Denmark) for 10 minutes. The reaction was quenched in 
water. The slides were counterstained with hematoxylin, 
rinsed with ammonium water for color enhancement, 
dehydrated through a series of ethanol and xylene, and 
coverslipped.
Western blotting
PARP1 protein expression was analyzed by 
Western blotting. Cells were lysed in homemade 
RIPA buffer (50mM Tris/HCL pH 7.5; 1% NP-40; 0.5 
% Na-deoxycholate; 150 mM NaCL; 0.05 % SDS), 
supplemented with 1 mM Pefabloc SC (Roche Applied 
Science, Indianaoplis, IN, USA). Samples containing 
equal amounts of protein were separated on a 10% SDS–
PAGE gel and blotted onto a PVDF membrane (Millipore, 
Amsterdam, The Netherlands). The membranes were 
blocked in TBS-Tween (20mM Tris; 137 mM NaCL 
pH 7.6; 0.1% Tween), containing 5% low fat dried milk 
and then incubated overnight at 4°C with an 1:3,000 
diluted antibody directed against PARP1 (#556362; BD 
Pharmingen, San Diego, CA, USA) or with an 1:10,000 
diluted  antibody  directed  against  β-actin  (Santa  Cruz 
Biotechnology, Santa Cruz, CA, USA). After several 
washes the membranes were incubated with 1:3,000 
diluted HRP-conjugated rabbit-anti mouse IgG (DAKO, 
Glostrup, Denmark). Antibody binding was detected using 
Amersham ECL Plus Western Blotting Detection System 
(GE Healthcare, Buckinghamshire, UK). 
Cell proliferation assay
A cell proliferation assay was used to measure 
Olaparib (AZD2281 - Axon Medchem, Groningen, 
The Netherlands) drug sensitivity. Cells were plated at 
a concentration of 4,000 cells/ml for KNS42 and 2,000 
cells/ml for SF188, UW479, Res196 and UW228-2 
in 96-wells cell culture plates (Greiner Bio-One B.V., 
Alphen a/d Rijn, The Netherlands). After 24 hours, cells 
were  treated  with  Olaparib  (0  –  10  μM  dissolved  in 
DMSO). After 96 hours, plates were washed with PBS 
using a cell washer (AquaMax®4000, MDS Analytical 
Technologies Inc., Sunnyvale, CA, USA) and fixed with 
4% formaldehyde (VWR International SAS, Fontenay-
sous-Bois, France). After washing with PBS, cells were 
incubated for 30 minutes with DAPI (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) diluted 1:3,000 in PBS 
using a reagent dispenser (Multidrop® Combi; Thermo 
Scientific,  Waltham,  MA,  USA).  Cells  were  counted 
using the Acumen eX3 laser scanning cytometer (TTP 
LabTech LTD, Melbourn, UK). Cell proliferation of in 
suspension growing medulloblastoma cell line D283-med 
was assessed using T25 culture flasks. Cells were seeded 
in 5 ml in T25 culture flasks, in a concentration of 50,000 
cells/ml, in duplicate. After 24 hours, cells were treated 
with Olaparib (0 – 10 μM dissolved in DMSO). After 96 
hours, cells were counted with a CASY® Cell Counter 
(Schärfe System, Germany).
To assess radiosensitizition with Olaparib, the cell 
proliferation assay using the Acumen eX3 laser scanning 
cytometer was used for KNS42 and Res196, and the 
CASY® Cell Counter for D283-med. At 24 hours after 
plating, Olaparib (0 - 8 μM) was added and cells were 
irradiated (0 – 6 Gy) 2 hours later, using a Gammacell 
220 Excel (MDS Nordion, Ottowa, Canada). A 7-day 
growth curve was distilled from daily counts. Slope of the 
exponential growth was calculated per drug concentration, 
normalized to non-irradiated controls and plotted against 
radiation dose and analyzed using GraphPad Prism 
software (GraphPad Software Inc., San Diego, CA, USA). 
Analysis of inhibitory concentrations was performed 
using SigmaPlot 11.0 (Systat Software, Inc. San Jose, CA, 
USA). Triplicate experiments were performed for each 
cell line.
Clonogenic assay
The radiosensitizing effect of PARP inhibition in 
Res196 cells was measured using a clonogenic assay. 
To assess clonogenic survival, exponentially growing 
Res196 cells were trypsinized, plated in triplicate in 6 
wells plates at concentrations from 125/250 cells per 
well (0 Gy) to 2,000/4,000 cells (6 Gy) and allowed to 
attach for 4 hours. Olaparib (pre)treatment and radiation 
was applied as in the cell proliferation assay. Cells were 
grown for 10 days, fixed with 3.75% paraformaldehyde 
and stained with Giemsa stain modified solution (Fluka). 
Colonies of more than 50 cells were counted by an 
automated reader (Bioreader® 5000i; BIO-SYS, Karben 
Germany). This method was validated by a manual cell 
count  giving  comparable  results.  Plating  efficiency 
(PE) was calculated by dividing the number of colonies 
counted by the number of cells plated. Surviving fractions 
(SF) were then calculated by dividing the PE by the PE of 
the non-irradiated control per drug concentration. 
Immunofluorescence for γH2AX foci detection
Cells  were  grown  on  coverslips  and  fixed  in  4% 
methanol-free formaldehyde in PBS for 30 minutes, 
permeabilized with 0.1% Triton X-100 in PBS for 5 Oncotarget 2011; 2:  984 - 996 987 www.impactjournals.com/oncotarget
minutes, blocked with 5% FBS in PBS for 10 minutes 
and washed. Incubation with primary antibody anti-
γH2AX (Millipore, Billerica, MA, USA) diluted 1:100 
in PBS-gelatin was performed overnight at 4°C. Cells 
were washed four times and incubated with fluorescein-
conjugated secondary antibody goat-anti-mouse antibody 
(1:200; DAKO, Glostrup, Denmark). Cells were rinsed 
thoroughly with PBS, treated for 5 minutes with DAPI 
diluted in PBS (1:10,000). Fluorescence was visualized 
with a Zeiss Axioskip microscope (HBO100W/Z), 
equipped with a Canon digital camera (Canon PowerShot 
A640, Canon Inc., Tokyo, Japan) as well as imaging 
software (Canon Utilities, ZoomBrowser Ex. 5.7, Canon 
Inc., Nort Ryde, Australia). The number of γH2AX foci 
was counted manually.
Statistics
Survival data were available from pediatric 
medulloblastoma, ependymoma and HGG gene 
expression datasets[24, 25, 28], enabling the correlation 
between PARP1 expression and outcome. For HGG, 
cases that were a result of previous cranial radiation were 
excluded. The quantitative variable PARP1 expression was 
dichotomized according to the best cutoff value obtained 
by the receiver operating characteristics (ROC) analysis 
using the life status (dead vs alive) or the event of relapse 
(presence vs absence of relapse) as the outcome variable, 
respectively. Impact of high PARP1 expression on overall 
survival (OS) was determined using Kaplan Meier analysis 
and differences between groups were calculated using the 
log-rank test. Statistical tests were performed using SPSS 
software (version 15) and 2-sided calculated p values 
<0.05 were considered to be statistically significant. 
RESULTS
PARP1 mRNA expression is relatively high in 
pediatric brain tumors compared to normal brain 
tissue 
PARP1 mRNA expression in pediatric brain tumors 
and non-malignant brain tissues was determined by in 
silico analysis of publicly available microarray data[24-
27], using R2 analysis software. PARP1 was found to 
be expressed in normal adult brain. Similar expressions 
were found for adolescent dorsolateral prefrontal cortex 
consisting of neuronal and glial cells and non malignant 
cerebellum. The PARP1  expression  was  significantly 
higher in pediatric ependymoma and medulloblastoma, 
compared to cortex and cerebellum, while PARP1 
expression in HGG was significantly higher compared to 
normal cortex. (Figure 1). 
High PARP1 mRNA expression is associated with 
poor outcome in pediatric HGG, medulloblastoma 
and ependymoma
For 55 medulloblastoma, 74 ependymoma and 38 
pediatric HGG cases both microarray expression data and 
specific outcome data were available[24, 25, 28]. In order 
to determine the impact of PARP1 on survival, PARP1 
expression data were dichotomized on high versus low 
expression for each tumor type. 
In the medulloblastoma dataset, in the PARPhigh 
group (n = 35) 15 patients died (42.9%) while in the 
PARP1low group (n = 20) 5 patients died (25%). Kaplan-
Meier survival analysis showed a trend to worse overall 
survival in patients with high PARP1 mRNA expression 
(n=28) (p=0.073). In the ependymoma dataset, in the 
PARPhigh group (n = 9) 4 patients died (44.4%) while in 
the PARP1low group (n = 65) 14 patients died (21.5%). 
Again a trend was observed in the Kaplan-Meier survival 
analysis to worse overall survival in patients with high 
PARP1 mRNA expression (p=0.073). For pediatric HGG 
an even stonger association with PARP expression was 
observed. In the PARPhigh group (n = 22) 21 patients died 
(95.9%) while in the PARP1low group (n = 16) 11 patients 
died (68.7%). Kaplan-Meier survival analysis showed a 
Figure 1: In silico analysis of PARP1 mRNA 
expression  using  R2  analysis  software  on  datasets 
of non-malignant brain tissues of cerebral cortex 
and cerebellum (grey), versus datasets of childhood 
ependymoma, medulloblastoma and high grade 
glioma (dark grey). 
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Figure 2: Kaplan Meier survival curves using R2 analysis software showing the overall survival probability for high 
(black) versus low (grey) PARP1 mRNA expression, in patients with medulloblastoma, ependymoma and high grade 
glioma respectively. High levels of PARP1 showed a clear trend towards worse overall survival in medulloblastoma (P=0.073) and 
ependymoma (P=0.083) and were significantly correlated with a worse prognosis in pediatric HGG (P=0.009).
Figure 3: PARP1 immunohistochemistry on paraffin embedded sections. Representative images of PARP1 staining in (A) 
cerebellum, (B) cerebral cortex, with strong nuclear staining of oligodendrocytes (*) and weak nuclear staining of astrocytes (**) and 
neurons (***), strong nuclear staining in (C) anaplastic ependymoma, (D) anaplastic astrocytoma and (E) medulloblastoma.Oncotarget 2011; 2:  984 - 996 989 www.impactjournals.com/oncotarget
significantly  worse  overall  survival  in  pediatric  HGG 
patients with high PARP1 mRNA expression (p=0.009) 
(Figure 2).
PARP1 protein expression in primary tumor 
samples
PARP1 protein expression was determined by 
immunohistochemistry in non-malignant brain tissues 
and pediatric CNS tumors (Figure 3). Non-malignant 
cerebellum showed cytoplasmic staining of Purkinje cells 
and weak staining of cerebellar neurons; granule cells were 
completely negative for PARP1. In normal neo-cortex 
only oligodendrocytes showed a strong positive nuclear 
staining for PARP1. Astrocytes and neurons had a weak 
PARP1 expression. The pediatric CNS tumors revealed 
a relatively strong PARP1 protein expression. Within 
tumor tissue sections from pediatric HGG, ependymoma 
and medulloblastoma patients, a comparable strong 
nuclear staining pattern was observed, which was scored 
semi-quantitatively based on intensity and percentage 
of positive cells. Results of this scoring system are 
summarized in table 1. In 7 out of 8 HGG tissue sections 
a strong to intensive nuclear staining was seen in at least 
50% of cells. In tissue sections derived from ependymoma 
patients a similar tendency towards strong and abundant 
nuclear PARP1 staining was observed: in 16 out of 18 
sections a convincing nuclear PARP1 staining was found 
in at least 30% of tumor cells. In medulloblastoma a more 
varied staining pattern was found, with a higher number 
of sections showing moderate nuclear PARP1 staining. 
Despite a larger variation in the percentage of positive cell 
nuclei, a majority of sections demonstrated positive nuclear 
PARP1 staining (61 out of 84 sections). Analogous to the 
mRNA expression, ependymoma samples show overall 
very high protein expression. Medulloblastoma and HGG 
are more variable but overall also highly express PARP1.
Pediatric brain tumor cell lines are differentially 
sensitive to PARP inhibition with Olaparib.
We examined PARP1 protein expression in different 
pediatric brain tumor cell lines by Western Blot analysis 
(Figure 4). D283-med and UW228-2 medulloblastoma 
cells, Res196 ependymoma cells and SF188, KNS42 
and UW479 HGG cells were used. In all cell lines 
Staining
% Positive cells Negative Moderate Strong Intensive
Pediatric HGG 
(n=8)
< 10 % 1 0 0 0
10-50% 0 0 0
50-90% 0 1 1
> 90% 0 0 5
Ependymoma 
(n=18) 
< 10 % 3 0 0 0
10-50% 0 0 1
50-90% 0 1 1
> 90% 0 1 11
Medulloblasto
ma (n=84) 
< 10 % 8 0 1 0
10-50% 2 3 1
50-90% 12 11 5
> 90% 1 15
25
Table 1: Overview of semiquantitative scoring of immunohistochemical PARP1 staining in pediatric HGG, 
ependymoma, and medulloblastoma patient material. The intensity of nuclear PARP1 staining (negative/moderate/strong/
intensive) and the percentage of positive nuclei was determined by two independent reviewers (DVV/OM).Oncotarget 2011; 2:  984 - 996 990 www.impactjournals.com/oncotarget
PARP1 protein expression was detected, in particular in 
ependymoma cell line Res196 and medulloblastoma cell 
line D283-med (Figure 3). 
To determine the  effect of PARP inhibition on 
cell proliferation we first exposed the cells to the PARP 
inhibitor Olaparib as a single agent. In figure 5 the effect 
of Olaparib treatment on six pediatric brain tumor cell 
lines is shown. The HGG cell line SF188 showed high 
sensitivity to Olaparib treatment as compared to the other 
cell lines, with a 50% inhibitory concentration (IC50) of 
1.42  μM.  The  medulloblastoma  cell  line  D283-med  is 
also highly sensitive, with an IC50 value of 2.25 μM. HGG 
cell lines KNS42 and UW479 are less sensitive, with IC50 
values of 6.74 μM and 7.43 μM respectively. A comparable 
sensitivity was observed in the medulloblastoma cell 
line UW228-2 for which an IC50 of 6.80 μM was found. 
Olaparib appeared to convey minimal toxicity in the 
ependymoma cell line Res196, with an IC50 value of 8.42 
μM.
PARP inhibition with olaparib sensitizes pediatric 
brain tumor cells to radiation 
To investigate whether a two hour pretreatment 
with Olaparib enhances radiosensitivity in ependymoma, 
HGG and medulloblastoma cell lines, clonogenic and cell 
proliferation assays were performed. Only ependymoma 
cell line Res196 was able to form clones in a clonogenic 
assay. Using this assay, Olaparib increased radiation 
sensitivity compared to the untreated control in a dose-
dependent fashion (p < 0.001) (Figure 6A). In the absence 
of irradiation, clonogenic capacity was reduced with 12%, 
18% and 40% in cells treated with 1, 4 and 8 μM Olaparib, 
PARP1
β actin
UW228-2       D283-med        Res196           SF188             KNS42          UW479         
113 kD
43 kD
Medulloblastoma Ependymoma High grade glioma
Figure 4: Immunoblot of baseline PARP1 (113 kD) and beta actin (42 kD) expression in pediatric brain tumor cell 
lines. 
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Figure 7. (A) Representative examples of immunofluorescent staining of γH2AX foci before, and (0.5 – 72 hours) after 4 Gy gamma 
radiation in KNS42 cells, pretreated with vehicle or 4 μM Olaparib. (B) Mean ± SE counts of γH2AX foci in KNS42, Res196 and D283-
cells. D283-med cells were pretreated with 1 μM Olaparib. One hour after radiation nuclei stained diffusely positive for γH2AX in D283-
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respectively (data not shown). Radiosensitizing capacity 
of Olaparib was also investigated in Res196 cells by a 
previously described cell proliferation assay[30](Figure 
6B). Like in the clonogenic assay, radiosensitization was 
observed in this assay: upon Olaparib treatment, a dose-
dependent decrease of exponential growth after radiation 
was observed in Res196 cells (Olaparib IC50 8.42 μM, 
Figure 5), even in subcytoxic concentrations of 1, 2 and 
4 μM.
Since the HGG cell line KNS42 and medulloblastoma 
cell line D283-med were not able to form clones, the cell 
proliferation assay was used in these cells. Results from 
the proliferation assay are shown in figure 6B. In HGG cell 
line KNS42 an even more profound effect was observed 
when cells were irradiated in the presence of Olaparib, 
indicating a stronger sensitizing effect towards radiation. 
Based on the toxicity data of Olaparib (Figure 5), showing 
an IC50 of 6.74 μM, treatment with 1 and 4 μM Olaparib 
showed the optimal radiation sensitizing effect in KNS42.
In medulloblastoma cell line D283-med, showing 
relatively strong sensitivity to Olaparib, with an IC50 
of 2.25 μM  doses  of  0.5  μM  to  4  μM  were  used  in 
combination with radiation. Again radiosensitization was 
observed, even in subcytotoxic concentrations of 0.5 μM 
(Figure 5B).
Pretreatment with Olaparib results in persistence 
of DNA damage after irradiation of pediatric 
brain tumor cells. 
In order to study the effect of PARP1 inhibition on 
the induction and persistence of DSBs in ependymoma, 
HGG and medulloblastoma cells, the presence of γH2AX 
foci  was  assessed  by  immunofluorescence.  In  HGG 
cell line KNS42, ependymoma cell line Res196 and 
medulloblastoma cell line D283-med, a rapid formation of 
γH2AX foci was observed minutes after ionizing radiation 
(Figure 7). A two hour pretreatment with 1 μM (D283-
med), or 4 μM (KNS42, Res196) Olaparib did not result in 
a significant difference of baseline DSB levels compared 
to untreated cells before radiation. However, one hour 
after irradiation a significantly higher number of DSBs 
was observed in Olaparib pretreated cell line Res196 and 
D283-med, a difference that persisted even up to 72 hours 
after radiation (Figure 7B). Cell line KNS42 showed an 
increasing difference in DSB later in time, with γH2AX 
foci count still rising at 72 hours after irradiation in cells 
pretreated with Olaparib. 
DISCUSSION
Here we show that PARP1 is expressed in high grade 
pediatric brain tumors, thereby indicating the rationale of 
PARP1 as a potential therapeutic target in these cancers. In 
silico analysis of PARP1 mRNA expression revealed higher 
PARP1 expression in pediatric brain tumors compared to 
non-malignant brain. Interestingly, high PARP1 mRNA 
expression was associated with poor disease outcome 
in a gene expression datasets of medulloblastoma, 
posterior fossa ependymoma and pediatric HGG, with 
high significance in the latter. As a validation of the gene 
expression data, we assessed PARP1 protein expression 
by immunohistochemistry in high grade pediatric brain 
tumors and tissues derived from non-malignant pediatric 
brain. Although subtypes of cells in non-neoplastic brain 
region showed some PARP1 positivity, an abundant and 
profusely intensive nuclear PARP1 staining was observed 
in tissues of pediatric brain tumors, especially HGG and 
ependymoma. Medulloblastoma tissue was more variable 
in PARP1 expression but compared to normal tissue it also 
generally showed strongly positive staining. 
In all pediatric brain tumor cell lines used in this 
study, strong PARP1 protein expression was demonstrated 
by Western Blot. 
The HGG cell line SF188, which showed a moderate 
PARP1 expression had a high sensitivity to Olaparib. 
Compared to the other, relatively resistant, HGG cell 
lines KNS42 and UW479 this intrinsic sensitivity to 
Olaparib was remarkable. It may be explained by the fact 
that the SF188 cell line has a focal deletion of the tumor 
suppressor gene NF1 (17q11.2) [31]. Inactivating NF1 
deletions or mutations have recently been shown in 23% 
of adult glioblastoma patient samples and 6% of pediatric 
HGG [24, 32]. Impairment of NF1 tumor suppressor 
gene function leads to Ras/RAF/MEK/ERK and Ras/
PI3K/AKT/PKB/mTOR pathway overexpression, thus 
affecting cell proliferation, growth and survival [33, 34]. 
Disturbances in these pathways indirectly impair DNA 
repair, which possibly explains the high sensitivity of 
SF188 to Olaparib [35]. Furthermore, in the study by 
Bax et al., a point mutation in TP53 (17p13) was found 
in this cell line, impairing apoptosis and hampering G1 
arrest [31]. Although Bax et al showed the HGG cell line 
KNS42 to harbor the same p53 mutation, KNS42 revealed 
a much lower sensitivity to Olaparib. The genetic profile 
of SF188 and its high sensitivity to Olaparib found in our 
study, suggests a cooperative effect of PARP inhibition on 
one side and loss of NF1 and TP53 on the other, leading 
to synthetic lethality. Xenograft studies have shown 
that NF1 inactivation in mutationally p53 inactivated 
mice induced malignant astrocytomas and secondary 
malignant tumors after radiation [36, 37]. Future research 
is warranted to determine if loss of NF1 indeed conveys 
specific sensitivity to PARP inhibition. 
Defects in DSB repair in pediatric brain tumors, 
providing rationale of synthetic lethality with PARP1 
inhibition are to be explored. Recently, low-level gains in 
PARP1 were identified in a subset of patients suffering 
from diffuse intrinsic pontine glioma (DIPG), using a 
whole-genome single nucleotide polymorphism (SNP) 
– based microarray. Multiple deletions or LOH in genes Oncotarget 2011; 2:  984 - 996 993 www.impactjournals.com/oncotarget
involved in HR, such as BRCA1/2, RAD50, RAD51L1, 
and in NHEJ, such as LIG4, XRCC4 and XRCC5, 
were observed in this SNP-array, making exploration 
of PARP inhibition in these tumors even more relevant. 
Furthermore, in DIPG, phosphatase and tensin homolog 
(PTEN) loss was observed in 8-57% in small case series 
[38-40]. Loss of PTEN through deletion or mutation in 
supratentorial pediatric HGG is more rare than in DIPG, 
but if present, associated with poor overall survival [41]. 
As a transcriptional regulator of RAD51, PTEN is involved 
in DSB repair and preservation of chromosomal integrity. 
Lack of PTEN function compromises homologous 
recombination through decreased expression of RAD51. 
In this respect, PTEN loss is described to be an indicator 
of PARP inhibitor sensitivity [42-45].
As in the HGG cell line SF188, an almost similar 
degree of sensitivity to treatment with Olaparib as a single 
agent was seen in the medulloblastoma cell line D283-
med. Recently, a number of studies were conducted to 
gain more knowledge on distinct gene expression profiles 
of medulloblastoma, thereby improving the molecular 
classification  of  these  tumors  [25,  46-48].  Our  data 
indicate that PARP1 inhibition is a potential treatment 
target for high-risk patients and this will be even more 
relevant in combination with radiation. In this study 
a  significant  radiation  sensitizing  effect  of  treatment 
with the PARP1 inhibitor Olaparib was demonstrated in 
medulloblastoma, HGG and ependymoma cell lines. For 
the evaluation of radiation sensitivity, two distinctive 
methods were used. The clonogenic assay is regarded 
as the gold standard for the determination of radiation 
sensitivity [49]. This method assesses the ability of 
neoplastic stem cells for self-renewal and regrowth after 
treatment, thought to be the major causes for treatment 
failure and tumor recurrence in patients. An alternative 
method to the clonogenic assay is the assessment of cell 
proliferation after irradiation, providing information on the 
proliferative capacities of surviving cells after radiation 
[30]. Here we show that Olaparib sensitizes ependymoma 
cell line Res196 to irradiation in both assays, supporting 
the use of the cell proliferation assay as a method to 
study radiation sensitization. This radiosensitizing effect 
was also observed in pediatric HGG cell line KNS42 
and, to a larger extent, medulloblastoma cell line D283-
med. Olaparib sensitized these cells in subcytotoxic 
concentrations, proving its virtue as a true radiosensitizing 
drug.
PARP1 is well known for its prominent role in the 
repair of SSBs. Meanwhile, its importance in DSB repair 
is gradually emerging [50, 51]. We assessed the effect 
of Olaparib on the preservation of DNA damage by 
visualizing γH2AX foci. All cells treated with Olaparib 
showed persistence of radiation induced DSBs, up to 72 
hours after exposure to irradiation, whereas untreated 
cells were able to repair most of the damage. Persistence 
of DSBs in the Olaparib treated cells can be explained 
by two distinct mechanisms. First, impairment of SSB 
repair by PARP1 inhibition and consequent collapse of 
the replication fork leads to the formation of DSBs. The 
observed accumulation of yH2AX foci in KNS42 cells 
might be explained by this phenomenon. Alternatively, 
inhibition of PARP1 is suggested to lead to the binding of 
Ku to radiation induced DSBs, thereby preventing DSB 
repair by HR [52]. 
Tolerability and efficacy of PARP1 inhibitor Olaparib 
in cancer treatment has now been confirmed in adult phase 
I and II clinical trials [53, 54]. Since the use of PARP1 
inhibitors in cancer treatment is still in an experimental 
phase, the long-term effects of PARP1 inhibition have not 
yet become apparent. Currently, a clinical trial in the USA 
is  exploring  efficacy  of  oral  PARP  inhibitor  Veliparib 
(ABT-888) in combination with temozolomide in pediatric 
patients with recurrent or refractory CNS tumors [19]. 
Especially in the treatment of childhood cancer, long 
term-effects should be taken into serious consideration. 
From this perspective it is of importance to get more 
insight in PARP1 expression and function in developing, 
non-malignant brain tissues. This is necessary to 
determine the therapeutic index of PARP1 inhibitors, 
especially when used in combination with other DNA 
damaging agents. Recently, studies have shown that 
inhibition of PARP1 could convey a specific therapeutic 
benefit for the central nervous system. Following acute 
oxidative stress, such as radiation, neurons are described 
to have excessive synthesis of PAR by overactive PARP-1, 
leading to NAD+/ATP depletion and subsequent neuronal 
cell death. PARP inhibition has therefore been opted as a 
neuroprotective strategy for cerebral ischemia and several 
neurodegenerative diseases, such as Parkinson’s disease 
and ALS [55, 56]. 
In conclusion, our study provides evidence that 
PARP1 inhibition with Olaparib enhances radiation 
sensitivity of pediatric ependymoma, medulloblastoma 
and pediatric HGG cells in vitro, thereby providing 
the basis for further in vivo studies, aiming at clinical 
trials combining PARP inhibitors upfront with (chemo)
radiotherapy. This is a very important finding since some 
radiation resistant pediatric brain tumors could profit from 
a sensitization drug like Olaparib. This will potentially 
lead to more effective therapies with the possibility to 
reduce radiotherapy, conveying a better therapeutic index, 
ultimately leading to better survival with a reduction of 
long term side effects. 
ACKNOWLEDGMENTS
We thank Dr Michael Bobola (Seattle Children’s 
Hospital, Seattle, Washington, USA), for provision of 
the pediatric ependymoma cell line Res196. We thank dr 
Darrell Bigner (Duke University, Durham, North Carolina, 
USA) for providing us with the medulloblastoma cell lines 
D283-med and D556-med.Oncotarget 2011; 2:  984 - 996 994 www.impactjournals.com/oncotarget
This  work  was  financially  supported  by  VUmc 
Cancer Center Amsterdam – VUmc Institute for Cancer 
and Immunology (VUmc CCA/V-ICI).
REFERENCE LIST
1.  Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger 
PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 
WHO  classification  of  tumours  of  the  central  nervous 
system. Acta Neuropathol. 2007; 114:97-109.
2.  Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger 
PC, Robertson PL, Bayer L, LaFond D, Donahue BR, 
Marymont MH, Muraszko K, Langston J, Sposto R. Phase 
III study of craniospinal radiation therapy followed by 
adjuvant chemotherapy for newly diagnosed average-risk 
medulloblastoma. J Clin Oncol. 2006; 24:4202-4208.
3.  Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, 
Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, 
Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, 
Dauser R et al. Risk-adapted craniospinal radiotherapy 
followed by high-dose chemotherapy and stem-cell rescue 
in children with newly diagnosed medulloblastoma (St 
Jude Medulloblastoma-96): long-term results from a 
prospective, multicentre trial. Lancet Oncol. 2006; 7:813-
820.
4.  Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, 
Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, 
Muraszko K, Puccetti D, Prados M, Chan KW. A phase 
II study of preradiotherapy chemotherapy followed by 
hyperfractionated radiotherapy for newly diagnosed high-
risk medulloblastoma/primitive neuroectodermal tumor: a 
report from the Children’s Oncology Group (CCG 9931). 
Int J Radiat Oncol Biol Phys. 2009; 74:1006-1011.
5.  Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford 
RA. Conformal radiotherapy after surgery for paediatric 
ependymoma: a prospective study. Lancet Oncol. 2009; 
10:258-266.
6.  Wolff JE, Driever PH, Erdlenbruch B, Kortmann RD, 
Rutkowski S, Pietsch T, Parker C, Metz MW, Gnekow A, 
Kramm CM. Intensive chemotherapy improves survival 
in pediatric high-grade glioma after gross total resection: 
results of the HIT-GBM-C protocol. Cancer. 2010; 
116:705-712.
7.  Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, 
Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey 
RS, Heideman RL. Temozolomide in the treatment of high-
grade gliomas in children: a report from the Children’s 
Oncology Group. Neuro Oncol. 2011; 13:317-323.
8.  Armstrong GT. Long-term survivors of childhood central 
nervous system malignancies: the experience of the 
Childhood Cancer Survivor Study. Eur J Paediatr Neurol. 
2010; 14:298-303.
9.  Gerber NU, Zehnder D, Zuzak TJ, Poretti A, Boltshauser 
E, Grotzer MA. Outcome in children with brain tumours 
diagnosed in the first year of life: long-term complications 
and quality of life. Arch Dis Child. 2008; 93:582-589.
10.  Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun 
LE. Late neurocognitive sequelae in survivors of brain 
tumours in childhood. Lancet Oncol. 2004; 5:399-408.
11.  Vinchon M, Baroncini M, Leblond P, Delestret I. Morbidity 
and tumor-related mortality among adult survivors of 
pediatric brain tumors: a review. Childs Nerv Syst. 2011; 
27:697-704.
12.  Merchant TE, Pollack IF, Loeffler JS. Brain tumors across 
the age spectrum: biology, therapy, and late effects. Semin 
Radiat Oncol. 2010; 20:58-66.
13.  Grill J, Renaux VK, Bulteau C, Viguier D, Levy-Piebois 
C, Sainte-Rose C, Dellatolas G, Raquin MA, Jambaque I, 
Kalifa C. Long-term intellectual outcome in children with 
posterior fossa tumors according to radiation doses and 
volumes. Int J Radiat Oncol Biol Phys. 1999; 45:137-145.
14.  Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier 
GG. PARP inhibition: PARP1 and beyond. Nat Rev 
Cancer. 2010; 10:293-301.
15. Sugimura K, Takebayashi S, Taguchi H, Takeda S, 
Okumura K. PARP-1 ensures regulation of replication fork 
progression by homologous recombination on damaged 
DNA. J Cell Biol. 2008; 183:1203-1212.
16.  Mansour WY, Rhein T, Dahm-Daphi J. The alternative 
end-joining pathway for repair of DNA double-strand 
breaks requires PARP1 but is not dependent upon 
microhomologies. Nucleic Acids Res. 2010; 38:6065-6077.
17.  Audebert M, Salles B, Calsou P. Effect of double-strand 
break DNA sequence on the PARP-1 NHEJ pathway. 
Biochem Biophys Res Commun. 2008; 369:982-988.
18.  Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst 
DG, O’Connor MJ, Wedge SR, Stratford IJ. Inhibition 
of PARP-1 by Olaparib (AZD2281) Increases the 
Radiosensitivity of a Lung Tumor Xenograft. Mol Cancer 
Ther. 2011; 10:1949-1958.
19. ClinicalTrials.gov.  http://clinicaltrials.gov/ct2/
results?term=parp
20.  O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, 
Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus 
chemotherapy in metastatic triple-negative breast cancer. N 
Engl J Med. 2011; 364:205-214.
21.  Barton VN, Donson AM, Kleinschmidt-DeMasters BK, 
Gore L, Liu AK, Foreman NK. PARP1 expression in 
pediatric central nervous system tumors. Pediatr Blood 
Cancer. 2009; 53:1227-1230.
22.  Pizem J, Popovic M, Cor A. Expression of Gli1 and PARP1 
in medulloblastoma: an immunohistochemical study of 65 
cases. J Neurooncol. 2011; 103:459-467.
23.  Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas 
HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle 
DA, Boddy AV, Clifford SC, Curtin NJ. Central nervous 
system penetration and enhancement of temozolomide 
activity in childhood medulloblastoma models by 
poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Oncotarget 2011; 2:  984 - 996 995 www.impactjournals.com/oncotarget
Cancer. 2010; 103:1588-1596.
24.  Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, 
Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe 
J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy 
RG et al. Integrated molecular genetic profiling of pediatric 
high-grade gliomas reveals key differences with the adult 
disease. J Clin Oncol. 2010; 28:3061-3068.
25.  Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van 
Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, 
Mrsic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch 
T,  Ellison  D  et  al.  Integrated  genomics  identifies  five 
medulloblastoma  subtypes  with  distinct  genetic  profiles, 
pathway signatures and clinicopathological features. PLoS 
One. 2008; 3:e3088.
26.  Harris LW, Lockstone HE, Khaitovich P, Weickert CS, 
Webster MJ, Bahn S. Gene expression in the prefrontal 
cortex during adolescence: implications for the onset of 
schizophrenia. BMC Med Genomics. 2009; 2:28.
27.  Roth RB, Hevezi P, Lee J, Willhite D, Lechner SM, Foster 
AC, Zlotnik A. Gene expression analyses reveal molecular 
relationships among 20 regions of the human CNS. 
Neurogenetics. 2006; 7:67-80.
28.  Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin 
R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, 
Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y 
et al. Delineation of two clinically and molecularly distinct 
subgroups of posterior fossa ependymoma. Cancer Cell. 
2011; 20:143-157.
29.  Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank 
A, Goff RD. O6-methylguanine-DNA methyltransferase, 
O6-benzylguanine, and resistance to clinical alkylators in 
pediatric primary brain tumor cell lines. Clin Cancer Res. 
2005; 11:2747-2755.
30.  Luttjeboer M, Lafleur MV, Kwidama ZJ, Van Rijn J, Van 
Den Berg J, Slotman BJ, Kaspers GJ, Cloos J. Strategies for 
the analysis of in vitro radiation sensitivity and prediction 
of interaction with potential radiation modifying agents. Int 
J Radiat Biol. 2010; 86:458-466.
31.  Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, 
Viana-Pereira M, Jones TA, Williams RD, Grigoriadis 
A, Vassal G, Workman P, Sheer D, Reis RM, Pearson 
AD, Hargrave D, Jones C. Molecular and phenotypic 
characterisation of paediatric glioma cell lines as models for 
preclinical drug development. PLoS One. 2009; 4:e5209.
32.  Comprehensive  genomic  characterization  defines  human 
glioblastoma genes and core pathways. Nature. 2008; 
455:1061-1068.
33.  Larizza L, Gervasini C, Natacci F, Riva P. Developmental 
abnormalities and cancer predisposition in neurofibromatosis 
type 1. Curr Mol Med. 2009; 9:634-653.
34.  Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase 
AKT pathway in human cancer. Nat Rev Cancer. 2002; 
2:489-501.
35.  Verheij M, Vens C, van Triest B. Novel therapeutics in 
combination with radiotherapy to improve cancer treatment: 
rationale, mechanisms of action and clinical perspective. 
Drug Resist Updat. 2010; 13:29-43.
36.  Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason 
RP, Messing A, Parada LF. Early inactivation of p53 
tumor suppressor gene cooperating with NF1 loss induces 
malignant astrocytoma. Cancer Cell. 2005; 8:119-130.
37. Nakamura JL, Phong C, Pinarbasi E, Kogan SC, 
Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, 
Shokat K, Houseman BT, Chao R, Pieper RO, Shannon 
K. Dose-dependent effects of focal fractionated irradiation 
on secondary malignant neoplasms in Nf1 mutant mice. 
Cancer Res. 2011; 71:106-115.
38.  Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur 
D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle 
B, Grundy R. Homozygous loss of ADAM3A revealed 
by genome-wide analysis of pediatric high-grade glioma 
and diffuse intrinsic pontine gliomas. Neuro Oncol. 2011; 
13:212-222.
39.  Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, 
Huang A, Bouffet E, Hawkins C. Whole-genome profiling 
of pediatric diffuse intrinsic pontine gliomas highlights 
platelet-derived growth factor receptor alpha and poly 
(ADP-ribose) polymerase as potential therapeutic targets. 
J Clin Oncol. 2010; 28:1337-1344.
40. Louis DN, Rubio MP, Correa KM, Gusella JF, von 
Deimling A. Molecular genetics of pediatric brain stem 
gliomas. Application of PCR techniques to small and 
archival brain tumor specimens. J Neuropathol Exp Neurol. 
1993; 52:507-515.
41.  Thorarinsdottir HK, Santi M, McCarter R, Rushing EJ, 
Cornelison R, Jales A, MacDonald TJ. Protein expression 
of platelet-derived growth factor receptor correlates with 
malignant histology and PTEN with survival in childhood 
gliomas. Clin Cancer Res. 2008; 14:3386-3394.
42.  Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, 
Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay 
A, Lord CJ, Ashworth A, Reis-Filho JS. PTEN deficiency 
in endometrioid endometrial adenocarcinomas predicts 
sensitivity to PARP inhibitors. Sci Transl Med. 2010; 
2:53ra75.
43. McEllin B, Camacho CV, Mukherjee B, Hahm B, 
Tomimatsu N, Bachoo RM, Burma S. PTEN loss 
compromises homologous recombination repair in 
astrocytes: implications for glioblastoma therapy with 
temozolomide or poly(ADP-ribose) polymerase inhibitors. 
Cancer Res. 2010; 70:5457-5464.
44.  Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, 
Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. 
Synthetic lethal targeting of PTEN mutant cells with PARP 
inhibitors. EMBO Mol Med. 2009; 1:315-322.
45.  Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi 
PP, Yin Y. Essential role for nuclear PTEN in maintaining 
chromosomal integrity. Cell. 2007; 128:157-170.Oncotarget 2011; 2:  984 - 996 996 www.impactjournals.com/oncotarget
46.  Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart 
CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French 
P,  Rutka  JT,  Pfister  S,  Taylor  MD.  Medulloblastoma 
comprises four distinct molecular variants. J Clin Oncol. 
2011; 29:1408-1414.
47.  Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein 
D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, 
Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson 
RJ. Genomics identifies medulloblastoma subgroups that 
are enriched for specific genetic alterations. J Clin Oncol. 
2006; 24:1924-1931.
48.  Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, 
Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, 
Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, 
Ogg R et al. Subtypes of medulloblastoma have distinct 
developmental origins. Nature. 2010; 468:1095-1099.
49.  Franken NA, Rodermond HM, Stap J, Haveman J, van Bree 
C. Clonogenic assay of cells in vitro. Nat Protoc. 2006; 
1:2315-2319.
50.  Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, 
Seluanov A, Gorbunova V. SIRT6 promotes DNA repair 
under stress by activating PARP1. Science (New York, 
NY. 2011; 332:1443-1446.
51. Couto CA, Wang HY, Green JC, Kiely R, Siddaway 
R, Borer C, Pears CJ, Lakin ND. PARP regulates 
nonhomologous end joining through retention of Ku at 
double-strand breaks. The Journal of cell biology. 2011; 
194:367-375.
52. Hochegger H, Dejsuphong D, Fukushima T, Morrison 
C, Sonoda E, Schreiber V, Zhao GY, Saberi A, Masutani 
M, Adachi N, Koyama H, de Murcia G, Takeda S. Parp-
1 protects homologous recombination from interference 
by Ku and Ligase IV in vertebrate cells. EMBO J. 2006; 
25:1305-1314.
53.  Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, 
Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler 
RK, Wardley A, Mitchell G, Earl H, Wickens M, 
Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor 
olaparib in patients with BRCA1 or BRCA2 mutations and 
advanced breast cancer: a proof-of-concept trial. Lancet. 
2010; 376:235-244.
54.  Audeh MW, Carmichael J, Penson RT, Friedlander M, 
Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin 
A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens 
M, Tutt A. Oral poly(ADP-ribose) polymerase inhibitor 
olaparib in patients with BRCA1 or BRCA2 mutations and 
recurrent ovarian cancer: a proof-of-concept trial. Lancet. 
2010; 376:245-251.
55.  Koh DW, Dawson TM, Dawson VL. Poly(ADP-ribosyl)
ation regulation of life and death in the nervous system. 
Cell Mol Life Sci. 2005; 62:760-768.
56. Egi Y, Matsuura S, Maruyama T, Fujio M, Yuki S, 
Akira T. Neuroprotective effects of a novel water-soluble 
poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in 
vitro and in vivo models of cerebral ischemia. Brain Res. 
2011; 1389:169-176.